Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Merck & Co. and Yumanity Therapeutics will jointly develop neurodegenerative disease treatments. Their deal, which includes an undisclosed up-front payment, gives Merck access to two preclinical Yumanity programs: an amyotrophic lateral sclerosis treatment and a therapy for frontotemporal lobar dementia. Yumanity launched in 2014 to target the misfolded proteins common in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Last year, the company moved its first drug candidate, for Parkinson’s, into Phase I clinical trials.
This article has been sent to the following recipient: